This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rughetti, A. Articles by Nuti, M. Search for Related Content PubMed PubMed Citation Articles by Rughetti, A. Articles by Nuti, M.

Human B-Cell Immune Response to the Polymorphic Epithelial Mucin¹

Department of Experimental Medicine, University of Rome, viale Regina Elena 324, 00161 Rome [A. R., V. T., L. F.]; Department of Developmental and Cellular Biology, via degli Apuli I, Rome [C. A. G.]; Department of Obstetric and Gynecology, Catholic University of Rome, L. go A. Gemelli 8, Rome [G. S., P. B. P., S. M.]; Department of Molecular Biology, University of Siena, Siena [G. R.]; and Department of Biomedicine, Section of Pathology, University of Pisa, via Roma 55. 56126 Pisa [M. N.], Italy

Human antibodies generated by Epstein-Barr virus immortalized B-cells from tumor-draining lymph nodes of an ovarian cancer patient were screened for reactivity in enzyme-linked immunosorbent assay with a synthetic peptide corresponding to the protein core of the polymorphic epithelial mucin. Epitopes within this region are in fact considered tumor specific since they are selectively exposed in tumor cells due to aberrant glycosylation. Human antibody BB5, thus selected, reacts in enzyme-linked immunosorbent assay and immunohistochemistry with polymorphic epithelial mucin-expressing tumor cells. This is the first demonstration of the existence of a B-cell immune response to selected epitopes of polymorphic epithelial mucin and, together with the cytotoxic T-cell response already demonstrated, constitutes the basis for the use of synthetic peptides as a vaccine in cancer patients.

¹ This work was supported by Associazione per la Ricerca sul Cancro and CNR ACRO No. 92.02227.PF39.

² To whom requests for reprints should be addressed.

Received 3/ 8/93. Accepted 4/28/93.

This article has been cited by other articles:

				T. L. Tinder, D. B. Subramani, G. D. Basu, J. M. Bradley, J. Schettini, A. Million, T. Skaar, and P. Mukherjee MUC1 Enhances Tumor Progression and Contributes Toward Immunosuppression in a Mouse Model of Spontaneous Pancreatic Adenocarcinoma J. Immunol., September 1, 2008; 181(5): 3116 - 3125. [Abstract] [Full Text] [PDF]

				M. A. Tarp, A. L. Sorensen, U. Mandel, H. Paulsen, J. Burchell, J. Taylor-Papadimitriou, and H. Clausen Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat Glycobiology, February 1, 2007; 17(2): 197 - 209. [Abstract] [Full Text] [PDF]

				A. L. Sorensen, C. A. Reis, M. A. Tarp, U. Mandel, K. Ramachandran, V. Sankaranarayanan, T. Schwientek, R. Graham, J. Taylor-Papadimitriou, M. A. Hollingsworth, et al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance Glycobiology, February 1, 2006; 16(2): 96 - 107. [Abstract] [Full Text] [PDF]

				M. M. Soares, V. Mehta, and O. J. Finn Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection J. Immunol., June 1, 2001; 166(11): 6555 - 6563. [Abstract] [Full Text] [PDF]

				P. Mukherjee, A. R. Ginardi, C. S. Madsen, C. J. Sterner, M. C. Adriance, M. J. Tevethia, and S. J. Gendler Mice with Spontaneous Pancreatic Cancer Naturally Develop MUC-1-Specific CTLs That Eradicate Tumors When Adoptively Transferred J. Immunol., September 15, 2000; 165(6): 3451 - 3460. [Abstract] [Full Text] [PDF]

				S. von Mensdorff-Pouilly, A. A. Verstraeten, P. Kenemans, F. G. M. Snijdewint, A. Kok, G. J. Van Kamp, M. A. Paul, P. J. Van Diest, S. Meijer, and J. Hilgers Survival in Early Breast Cancer Patients Is Favorably Influenced by a Natural Humoral Immune Response to Polymorphic Epithelial Mucin J. Clin. Oncol., February 1, 2000; 18(3): 574 - 574. [Abstract] [Full Text] [PDF]

				Y. HIRASAWA, N. KOHNO, A. YOKOYAMA, K. KONDO, K. HIWADA, and M. MIYAKE Natural Autoantibody to MUC1 Is a Prognostic Indicator for Non-Small Cell Lung Cancer Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): 589 - 594. [Abstract] [Full Text]

				T. Kokubo, K. Hashizume, H. Iwase, K. Arai, A. Tanaka, K. Toma, K. Hotta, and Y. Kobayashi Humoral immunity against the proline-rich peptide epitope of the IgA1 hinge region in IgA nephropathy Nephrol. Dial. Transplant., January 1, 2000; 15(1): 28 - 33. [Abstract] [Full Text] [PDF]

				T. Kokubo, Y. Hiki, H. Iwase, A. Tanaka, J. Nishikido, K. Hotta, and Y. Kobayashi Exposed peptide core of IgA1 hinge region in IgA nephropathy Nephrol. Dial. Transplant., January 1, 1999; 14(1): 81 - 85. [Abstract] [PDF]